Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 8.1% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 13,931 shares of the pharmaceutical company's stock after purchasing an additional 1,041 shares during the period. Sequoia Financial Advisors LLC's holdings in Vertex Pharmaceuticals were worth $6,754,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Mascagni Wealth Management Inc. purchased a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $31,000. SJS Investment Consulting Inc. boosted its position in shares of Vertex Pharmaceuticals by 46.2% during the 1st quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company's stock worth $46,000 after purchasing an additional 30 shares during the period. Truvestments Capital LLC boosted its position in shares of Vertex Pharmaceuticals by 30.3% during the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after purchasing an additional 23 shares during the period. Mpwm Advisory Solutions LLC purchased a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $40,000. Finally, Minot DeBlois Advisors LLC purchased a new position in Vertex Pharmaceuticals in the 4th quarter valued at approximately $44,000. Hedge funds and other institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $441.30 on Friday. The company's fifty day moving average price is $454.50 and its 200 day moving average price is $458.82. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29. The firm has a market capitalization of $113.33 billion, a P/E ratio of -112.58 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the prior year, the business earned $4.76 earnings per share. Vertex Pharmaceuticals's revenue was up 2.6% compared to the same quarter last year. As a group, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several recent research reports. Bank of America raised their price target on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a research report on Monday, March 31st. The Goldman Sachs Group reissued a "buy" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. HC Wainwright reissued a "buy" rating and issued a $550.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, June 23rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $535.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Erste Group Bank cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd. Fourteen equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $511.62.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.